Viscous formulations and their use in needle-free injection
Formulations are described that are viscous and will benefit from needle-free delivery at high driving pressures. Conventional delivery of these viscous formulations by hypodermic syringes is inconvenient as well as painful. Formulations include those which have a viscosity of about 5 cS or more at about 20° C. and which can have 0.5 ml or more administered by a needle-free injector in about 0.1 second±0.02 seconds.
1. A method of improving dosing compliance, and reducing dosing cost, comprising:
(a) actuating a needle-free injector to inject a drug formulation through skin of a patient and into the patient; and
(b) allowing the formulation injected in step (a) to provide sustained release of the drug to the patient, wherein
(c) the formulation is characterized by a volume of 0.05 mL to 1.5 mL and a viscosity of 100 cS or more at 20° C.;
(d) the injection of step (a) into the patient occurring over a period of one second or less; and
(e) the needle-free injector comprising a channel, and a single exit opening with a ratio of channel length to exit opening diameter of less than ten.
2. The method of claim 1 , wherein the ratio of length to exit diameter is less than 7.
3. The method of claim 1 , wherein the ratio of length to exit diameter is less than 5.
4. The method of claim 1 , wherein the ratio of length to exit diameter is 1.7±20%.
5. The method of claim 1 , wherein the viscosity of the formulation is 1000 cS or more at 20° C.
6. The method of claim 1 , wherein actuating the injector results in extruding the formulation at a rate of 5,000 microliters or more per second.
7. The method of claim 1 , wherein the drug is a psychiatric drug.
8. The method of claim 7 , wherein the psychiatric drug is extruded through skin of a human psychiatric patient.
9. The method of claim 8 , wherein the psychiatric drug comprises risperidone.
10. The method of claim 8 , wherein actuating the injector results in extruding the formulation at a rate of 5,000 microliters or more per second and the volume of the formulation is from 0.1 mL to 1.5 mL.
11. The method of claim 8 , wherein actuating the injector results in extruding the formulation at a rate of 5,000 microliters or more per second and the volume of the formulation is about 0.5 mL.
12. The method of claim 8 , wherein actuating the injector results in extruding the formulation at a rate of 5,000 microliters or more per second and patient is suffering from a disease chosen from schizophrenia and Bi-polar disorder.
13. The method of claim 8 , wherein the psychiatric drug is selected from the group consisting of chlorpromazine, fluphenazine, mesoridazine, perphenazine, prochlorperazine, promazine, thioridazine/sulforidazine, trifluoperazine, indoles, butyrophenones, thioxanthenes, diphenylbutylpiperidines, loxapine)butyrophenones, indoles, benzamides, diazepines, oxazepines, thiazepines, aripiprazole, risperidone, paliperidone, zotepine, iloperidone, pharmaceutically acceptable salt and ester forms thereof, and combinations of two or more of these compounds.
14. The method of claim 13 , wherein the psychiatric drug is selected from the group consisting of molindone, azaperone, benperidol, droperidol, haloperidol, flupentixol, chlorprothixene, thiothixene, zuclopenthixol, fluspirilene, penfluridol, pimozide, loxapine, melperone, sertindole, ziprasidone, sulpiride, remoxipride, amisulpride, clozapine, olanzapine, quetiapine, and pharmaceutically acceptable salts and ester forms, and combinations thereof.
15. The method of claim 1 , wherein the drug is risperidone.
16. The method of claim 1 , wherein the patient is dosed once a month by actuating the needle-free injector.
17. The method of claim 16 , wherein the needle-free injector is a single use disposable device.
18. The method of claim 1 , wherein the drug formulation comprises sucrose acetate isobutyrate.
19. The method of claim 18 , wherein actuating the injector results in extruding the formulation at a rate of 5,000 microliters or more per second.
20. The method of claim 19 , wherein the formulation comprises risperidone.
21. The method of claim 1 , wherein actuating the injector results in extruding the formulation at a rate of 5,000 microliters or more per second and the volume of the formulation is from 0.1 mL to 1.5 mL.
22. The method of claim 1 , wherein actuating the injector results in extruding the formulation at a rate of 5,000 microliters or more per second and the volume of the formulation is about 0.5 mL.
23. The method of claim 1 , wherein actuating the injector results in extruding the formulation at a rate of 5,000 microliters or more per second and patient is suffering from a disease chosen from schizophrenia and Bi-polar disorder.
24. A method of treating a patient with a psychiatric disorder, comprising:
(a) actuating a needle-free injector to inject a drug formulation comprising risperidone and sucrose acetate isobutryrate through skin of a patient and into the patient; and
(b) allowing the formulation injected in step (a) to provide sustained release of the risperidone to the patient, wherein
(c) the formulation is characterized by a volume of 0.05 mL to 1.5 mL and a viscosity of 100 cS or more at 20° C.;
(d) the injection of step (a) into the patient occurring over a period of one second or less; and
(e) the needle-free injector comprising a channel, and a single exit opening with a ratio of channel length to exit opening diameter of less than ten.
25. The method of claim 24 , wherein the psychiatric disorder is selected from the group consisting of schizophrenia and bi-polar disorder.
26. The method of claim 24 , wherein the ratio of length to exit diameter is less than seven.
27. The method of claim 24 , wherein the ratio of length to exit diameter is less than five.
28. The method of claim 27 , wherein the formulation is injected into the patient in step (a) in 0.2 second or less.
29. The method of claim 28 , wherein the formulation has a volume of 0.5 ml.
30. The method of claim 24 , wherein the formulation is injected into the patient in step (a) in 0.5 second or less.
31. A method of treatment, comprising:
(a) actuating a needle-free injector to inject a drug formulation out of the injector and through skin of a patient and into the a patient; and
(b) allowing the formulation injected in step (a) to provide sustained release of the drug to the patient, wherein
(c) the formulation is characterized by a volume of 0.05 mL to 1.5 mL and a viscosity of 100 cS or more at 20° C.;
(d) the injection of step (a) into the patient occurring over a period of 0.5 second or less; and
(e) the needle-free injector comprising a channel, and a single exit opening with a ratio of channel length to exit opening diameter of less than seven.
32. A method of treatment, comprising:
(a) actuating a needle-free injector to inject a drug formulation out of the injector and through skin of a patient and into the a patient; and
(b) allowing the formulation injected in step (a) to provide sustained release of the drug to the patient, wherein
(c) the formulation is characterized by a volume of 0.05 mL to 1.5 mL and a viscosity of 100 cS or more at 20° C.;
(d) the injection of step (a) into the patient occurring over a period of 0.2 second or less; and
(e) the needle-free injector comprising a channel, and a single exit opening with a ratio of channel length to exit opening diameter of less than five.
33. The method of claim 32 , wherein the drug is a psychiatric drug.
34. A method of dosing a patient, comprising:
(a) actuating a needle-free injector to inject a drug formulation through skin of a patient and into the patient; and
(b) allowing the formulation injected in step (a) to provide sustained release of the drug to the patient, wherein
(c) the formulation is characterized by a volume of about 0.5 mL and a viscosity of 100 cS or more at 20° C.;
(d) the injection of step (a) into the patient occurring over a period of 0.1 second or less; and
(e) the needle-free injector comprising a channel, and a single exit opening with a ratio of channel length to exit opening diameter of less than ten.